Problems of Radiation Medicine and Radiobiology

O. I. Solodyannikova, V. V. Danilenko, G. G. Sukach

National Cancer Institute, 22/43 Lomonosova Str., Kyiv, 03022, Ukraine

ANALGESIC EFFECT OF VARIOUS RADIOPHARMACEUTICALS IN THE COMPLEX TREATMENT OF METASTATIC BONE DISEASE

Objective. The study objective was to investigate and compare the effectiveness of different radiopharmaceuticals in the treatment of metastatic bone disease.
Materials and methods. Cancer patients (n = 150, average age (55 ± 11.6) years, 95 females, 55 males) having got various primary tumors and metastatic bone disease were given medical treatment at the Department of Nuclear Medicine of the National Institute of Cancer. The ¹⁵³Sm, ³²Р, and ⁸⁹Sr radiopharmaceutical agents produced by the «Radiopreparats» enterprise (Republic of Uzbekistan) and Radioisotope Centre Polatom (National Centre for Nuclear Research, Poland) were administered to the patients. There were cases of breast cancer (n = 75), prostate cancer (n = 45), lung cancer (n = 10), kidney cancer (n = 4), cervical cancer (n = 5), and rectosigmoid cancer (n = 11) among the treated subjects. In 135 patients (90 %) the bone metastases were detected by osteoscintigraphy with ⁹⁹мTc- monodiphosphonate. In 15 cases the diagnosis of metastatic bone disease was verified by other radiology methods.
Results. The pain intensity rating scale (LACOMED) was used to assay the analgesic effect of various radiopharmaceuticals in metastatic bone disease. Results of treatment with ³²P, ⁸⁹Sr, and ¹⁵³Sm were included in a comparative analysis procedure. It was established that the level of pain syndrome ranged from 7–8 points on the LACOMED scale before treatment. Upon administration of radionuclide therapy the level of pain was reduced down to 3–5 points, namely with ³²P therapy it has decreased by 30.7 %, with ⁸⁹Sr by 33.2 %, and with ¹⁵³Sm by 41.5 % respectively. Time pattern of ¹⁵³Sm analgesic effectiveness was studied depending on the number of treatment sessions. The best value of analgesic effect of ¹⁵³Sm was registered after the first treatment session with a tendency to decrease after the second and significantly lower analgesic effects after the third session. Tolerance of ¹⁵³Sm was rated on the CTCNCA (v) 4.3 scale. The best tolerance was peculiar to ¹⁵³Sm corresponding to the «good» level according to a point assessment. When using ⁸⁹Sr the drug tolerance was lower, not requiring however the drug discontinuation. The ³²P radiopharmaceutical featured the lowest tolerance approaching the «satisfactory» rating. In 11 patients upon that the side effects were found significantly impairing the patient’s status, accordingly some extra measures were required. No decision to cancel the drug administration was made.
Conclusions. Radionuclide therapy with ¹⁵³Sm-oxabiphor agent can be used in the complex treatment of metastatic bone disease in cancer patients having got tumors of different localization. ¹⁵³Sm-oxabiphor is the most effective and best tolerable radiopharmaceutical agent in the pain treatment in metastatic bone disease in comparison with ³²P and ⁸⁹Sr preparations (р < 0.05).
Key words: metastatic bone disease, radionuclide therapy, phosphorus-32, strontium-89, samarium-153.

Problems of Radiation Medicine and Radiobiology.
2021;26:562-572. doi: 10.33145/2304-8336-2021-26-562-572

full text

1. Bobrova VM, Grushka GV, Stadnyk LL, Tkachenko GI, Luhovytska NI, Savchenko AS et al. [Dynamics of hematologic parameters in carrying out radionuclide therapy with 153Sm-oxabifor in cancer patients]. Ukrainian Radiological Journal. 2016;(Suppl 1):166. Ukrainian.
2. Siampanopoulou M, El-Mantani Ordoulidis S, Iakovou I. Dimasis N. Sioundas A, Gotzamani-Psarrakou A. Prognostic significance of serum angiogenin and Her-2 in 153-Samarium pain palliation therapy of bone metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 2):S502. URL: https://doi.org/10.1007/s00259-014-2901-9.
3. Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol. 2014;11(6):335-345. doі:10.1038/nrclinonc.2014.70.
4. Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses. Clin Oncol (R Coll Radiol). 2013;25(4):217-226. doі:10.1016/j.clon.2012.11.004.
5. Krzhivisky PI, Kanaev SV, Novikov SN, Jukova LI, Vasilev MV. The added value SPECT-CT in oncological patients with solitary bone lesions discovered on routine planar bone scintigraphy. Nucl Med Mol Imaging. 2014;41(Suppl 2):S583. doi: 10.1007/s00259-014-2901-9.
6. Soussan M. About the specificity of radiotracers for prostate cancer. Nucl Med Mol Imaging. 2017;44(12):2142-2143. doi: 10.1007/s00259-017-3784-3.
7. Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. Pharmaconomics. 2014;32(2):173-191. doі:10.1007/s40273-013-0121-y.
8. Liepe K. Single high dose versus repeated bone-targeted radionuclide therapy. Eur Nucl Med Mol Imaging. 2017;44(12):2144-2145. doi:10.1007/s00259-017-3815-0.
9. Pacilio M, Ventroni G, De Vincentis G, Cassano B, Pellegrini R, Di Castro E, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emiting (223) Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016;43(1):21-33. doi: 10.1007/s00259-015-3150-2.
10. Takahashi A, Miwa K, Sasaki M, Baba S. A Monte Carlo study on 223Ra imaging for unsealed radionuclide therapy. Med Phys. 2016;43(6):2965. doi: org/10.1118/1.4948682.
11. Yustinx R, Muylle K, editors. Europen Nuclear Medicine Guide. Vienna: EANM; 2018. 385 p.
12. Onukwugha E, Yong C, MullinsCD, Seal B, McNally D, Hussain A. Skeletal-related events and mortality among older men with advanced prostate cancer. J Geriatr Oncol. 2014;5:281-289. doі:org/10.1016/j.jgo.2014.03.002.
13. Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, et al. Natural history of skeletal-related events in patients with breast, lung or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013;21(12):3279-3286. doі:10.1007/s00520-013-1887-3.
14. Chatal J-F, Kraeber-Bodere F, Cheryl M, Habbad F. Alphatherapy, the new impetus to targeted radionuclide therapy? Eur Nucl Med Mol Imaging. 2018;45(8):1362-1364. doi: 10.1007/s00259-018-4026-z.